Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

Core Insights - Atossa Therapeutics has appointed Dr. Tessa Cigler to its board of directors, effective immediately, enhancing its expertise in breast cancer treatment [1][2] - Dr. Cigler's experience as a medical oncologist will support the acceleration of Atossa's (Z)-endoxifen development program, which includes four Phase 2 trials [2] - (Z)-endoxifen is a promising therapeutic agent derived from tamoxifen, showing potential for improved efficacy and tolerability in breast cancer treatment [3][4] Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for significant unmet medical needs in oncology, particularly breast cancer [5] - The company is advancing a proprietary oral formulation of (Z)-endoxifen that bypasses liver metabolism and stomach acidity, aiming for better therapeutic outcomes [4] - Atossa's (Z)-endoxifen is currently undergoing four Phase 2 trials, targeting various patient demographics, including those with ductal carcinoma in situ and ER+/HER2- breast cancer [4]